The authors examined data from more than 1.2 million patients, tracking individuals who had previously been hospitalized for heart failure and then returned later due to COVID-19. 

The new findings are part of a virtual conference being hosted by the American College of Cardiology. 

Researchers were able to predict, with considerable accuracy, each patient's 5- and 10-year risk of heart failure. 

Sold as Verquvo, the medication can help patients reduce their risk of cardiovascular death or hospitalization for heart failure.

New research, published in ESC Heart Failure, details why heart failure patients are a high-risk group and will benefit from vaccination. 

The researchers, sharing their work in the American Journal of Cardiology, suggested multiple reasons why this may be the case. 

The document, published in the Journal of the American College of Cardiology, includes updated data and new treatment strategies. 

"Being vaccinated is an important step in prevention," one specialist said.